U.S. markets close in 5 hours 41 minutes

Samsung Biologics Co.,Ltd. (207940.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
933,000.00+17,000.00 (+1.86%)
At close: 3:30PM KST
Show:
Balance Sheet
Cash Flow
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Breakdown
ttm
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Total Revenue
1,322,848,615
1,164,776,874
701,591,860
535,805,801
464,629,334
Cost of Revenue
781,145,742
748,700,763
509,584,425
390,645,859
332,829,273
Gross Profit
541,702,873
416,076,110
192,007,435
145,159,942
131,800,061
Operating Expense
151,536,529
123,289,556
100,265,047
89,481,197
65,820,659
Operating Income
390,166,344
292,786,554
91,742,388
55,678,745
65,979,402
Net Non Operating Interest Income Expense
-3,665,151
-2,945,158
-8,368,258
-6,187,402
4,265,889
Pretax Income
405,260,818
265,992,163
155,435,309
302,975,837
-115,994,753
Tax Provision
70,459,726
25,017,363
-47,468,790
78,866,642
-19,022,637
Net Income Common Stockholders
334,801,092
240,974,800
202,904,099
224,109,195
-96,972,116
Basic EPS
-
3.64k
3.07k
3.39k
-1.47k
Diluted EPS
-
3.64k
3.07k
3.39k
-1.47k
Basic Average Shares
-
66,165
66,165
66,165
66,165
Diluted Average Shares
-
66,165
66,165
66,165
66,165
Total Operating Income as Reported
390,166,344
292,786,554
91,742,387
55,678,745
65,979,402
Rent Expense Supplemental
-
-
-
-
236,744
Total Expenses
932,682,271
871,990,319
609,849,472
480,127,056
398,649,932
Net Income from Continuing & Discontinued Operation
334,801,092
240,974,800
202,904,099
224,109,195
-96,972,116
Normalized Income
336,805,653
245,865,269
202,578,714
224,429,726
-47,567,244
Interest Income
10,693,721
13,140,465
17,246,464
9,651,186
9,949,872
Interest Expense
14,358,873
16,085,623
25,614,722
15,838,589
5,683,983
Net Interest Income
-3,665,151
-2,945,158
-8,368,258
-6,187,402
4,265,889
EBIT
419,619,691
282,077,786
181,050,031
318,814,426
-110,310,770
EBITDA
572,590,466
-
-
-
-
Reconciled Cost of Revenue
781,145,742
748,700,763
509,584,425
390,645,859
332,829,273
Reconciled Depreciation
152,970,775
143,688,005
132,885,103
91,450,555
69,926,227
Net Income from Continuing Operation Net Minority Interest
334,801,092
240,974,800
202,904,099
224,109,195
-96,972,116
Total Unusual Items Excluding Goodwill
-2,426,425
-5,398,185
433,847
-433,330
-59,096,430
Total Unusual Items
-2,426,425
-5,398,185
433,847
-433,330
-59,096,430
Normalized EBITDA
575,016,891
431,163,976
313,501,287
410,698,311
18,711,887
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-421,865
-507,716
108,462
-112,799
-9,691,559